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The Novel Receptor TRAIL-R4 Induces NF-kB
and Protects against TRAIL-Mediated Apoptosis,
yet Retains an Incomplete Death Domain
et al., 1997b) and TRAIL-R2/DR5 (Pan et al., 1997a; Sher-
idan et al., 1997; Walczak et al., 1997), are capable of
mediating apoptosis. In contrast, the third TRAIL recep-
tor, TRAIL-R3/TRID/DcR1 (Degli-Esposti et al., 1997;
Pan et al., 1997a; Sheridan et al., 1997) is not able to
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51 University Street transduce an apoptotic signal directly because it lacks
a cytoplasmic domain. Indeed, some investigators haveSeattle, Washington 98101
proposed that TRAIL-R3 acts as a decoy receptor to
inhibit TRAIL signaling (Pan et al., 1997a; Sheridan et
al., 1997). To date there is no description of signalingSummary
TRAIL receptors that inhibit apoptosis.
In this report we describe the identification of a fourthA fourth member of the emerging TRAIL receptor fam-
TRAIL receptor, one that does not signal apoptosis, canily, TRAIL-R4, has been cloned and characterized.
signal NF-kB activation, and is capable of protectingTRAIL-R4 encodes a 386±amino acid protein with an
against TRAIL-mediated apoptosis.extracellular domain showing 58%±70% identity to
those of TRAIL-R1, TRAIL-R2, and TRAIL-R3. The
Resultssignaling capacity of TRAIL-R4 is similar to that of
TRAIL-R1 and TRAIL-R2 with respect to NF-kB activa-
Isolation of TRAIL-R4 cDNAtion, but differs in its inability to induce apoptosis. Yet
To determine whether additional members of the TRAILTRAIL-R4 retains a C-terminal element containing one
receptor family exist, we screened two cDNA librariesthird of a consensus death domain motif. Transient
known to encode the previously characterized TRAIL-overexpression of TRAIL-R4 in cells normally sensitive
R1 (Pan et al., 1997b), TRAIL-R2 (Pan et al., 1997a; Sheri-to TRAIL-mediated killing confers complete protec-
dan et al., 1997; Walczak et al., 1997), and TRAIL-R3tion, suggesting that one function of TRAIL-R4 may
(Degli-Esposti et al., 1997; Pan et al., 1997a; Sheridanbe inhibition of TRAIL cytotoxicity. Like TRAIL-R1 and
et al., 1997) with a probe encompassing the extracellu-TRAIL-R2, this receptor shows widespread tissue ex-
lar ligand-binding domain of TRAIL-R3. Multiple cDNApression. The human TRAIL-R4 gene has been mapped
clones were obtained encoding a type 1 transmembraneto chromosome 8p22-21, clustered with three other
protein with homology to the previously identified TRAILTRAIL receptors.
receptors. The new cDNA, referred to as TRAIL-R4, en-
codes a 386±amino acid (aa) protein with a predictedIntroduction
signal sequence cleavage site after serine 55, a 125 aa
cysteine-rich extracellular domain, a 31 aa extracellularThe process of programmed cell death, or apoptosis,
linker sequence, a 21 aa hydrophobic transmembraneis fundamental in developmental and homeostatic main-
region, and a 154 aa C-terminal cytoplasmic domaintenance of complex biological systems. Of particular
(Figure 1A). The extracellular domain of TRAIL-R4 con-interest is the role of apoptosis in the processes of im-
tains one partial and two complete cysteine-rich pseu-mune regulation. The tumor necrosis factor (TNF) family
dorepeats and shows the highest identity to the extra-of cytokines and receptors has been the center of much
cellular domains of TRAIL-R3 (70%), TRAIL-R2 (57%),attention, since several members of this family have
and TRAIL-R1 (58%) (Figure 1B). Significant homologybeen shown to be capable of regulating the apoptotic
was also observed with other members of the TNF re-signals that shape the immune system (Smith et al.,
ceptor (TNFR) family, especially TNFR1 and cytopathic1994; Nagata and Golstein, 1995; van Parijs and Abbas,
avian leukosis±sarcoma virus receptor-1 (CAR1) (Figure1996). TRAIL, the newest member of the TNF family of
1B). Three potential N-glycosylation sites were identifiedligands (Wiley et al., 1995), can induce apoptosis in a
(Figure 1A).wide variety of transformed cell lines of diverse lineage,
Two allelic variants of TRAIL-R4 were identified, dif-but does not appear to kill normal cells (Wiley et al.,
fering at residues 35 (proline/serine) and 310 (serine/1995; Pitti et al., 1996). This finding has been puzzling
leucine) (Figure 1A). These variations, located in the pu-since TRAIL message is expressed at significant levels
tative signal peptide sequence and the cytoplasmicin most normal tissues (Wiley et al., 1995), suggesting
domain, respectively, have been shown to have no ef-that regulation of TRAIL function takes place at the level
fect on receptor expression or ligand binding (data notof receptor expression.
shown).The recent cloning of three TRAIL receptors implies
The C-terminal cytoplasmic domain of TRAIL-R4 dis-a more complex scenario, one inwhich TRAIL may trans-
plays 58% identity to the cytoplasmic domains of bothduce different signalsvia different receptors. Two recep-
TRAIL-R1 and TRAIL-R2. However, TRAIL-R4 carriestors for TRAIL, TRAIL receptor 1 (TRAIL-R1)/DR4 (Pan
only a portion of the consensus death domain motif,
having lost 52 of the 76 amino acids that encode the
predicted TRAIL-R1 and TRAIL-R2 death domain (Wal-*To whom correspondence should be addressed (e-mail: mdeglies
posti@immunex.com). czak et al., 1997) (Figures 1A and 1C).
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Figure 1. TRAIL-R4 Is a New Member of the
TRAIL Receptor Family
(A) The nucleotide and amino acid sequence
of TRAIL-R4 is shown. Arrowhead, the pre-
dicted N-terminal leader cleavage site; dotted
underline, the transmembrane domain; boxes,
three potential N-glycosylation sites. Two al-
lelic variants of TRAIL-R4 have been identi-
fied; asterisks mark the polymorphic amino
acids. Solid underline, the 24amino acids that
correspond to the last portion of the pre-
dicted TRAIL-R death domain (Walczak et al.,
1997).
(B) Alignment of the extracellular domains of
the four TRAIL receptors, TNFR1, and CAR1
shows conservation of the cysteine-rich pseu-
dorepeats characteristic of the TNF receptor
family. Open boxes, conserved cysteine resi-
dues; black boxes, other amino acids that are
conserved in at least three of the members.
Predicted disulfide bonds are shown. The
sequence reported in this article and that of
the second allelic variant have been submit-
ted to GenBank with accession numbers:
AF021232, AF021233.
(C) Alignment of the complete cytoplasmic
domains of TRAIL-R1, TRAIL-R2, TRAIL-R4,
Fas, and TNFR1shows conservation of a por-
tion of the death domain in TRAIL-R4. Arrows,
the boundaries of the predicted TRAIL-R
death domain motif (Walczak et al., 1997);
black boxes, amino acids conserved in at
least three of the members.
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Figure 2. TRAIL-R4 Shows Widespread Tissue Expression
Northern analysis showing the distribution of TRAIL-R4 mRNA in
whole human tissues and tumor cell lines. The source of the mRNA
Figure 3. Equilibrium Binding Isotherms of TRAIL-R4is shown above each lane. The position of the 28S and 18S ribosomal
RNA species, as determined by methylene-blue staining, is marked TRAIL-R4-Fc bound to goat-anti-human-Fc immobilized to plastic
on the left; the position of RNA size markers is shown on the right. was used in equilibrium binding assays with LZ-TRAIL plus 125I-
A TRAIL-R4 transcript of 4.0 kb is detected in most tissues and in labeled M15 anti-LZ antibody, as described (see Experimental Pro-
some tumor cell lines. cedures). The binding data plotted in the Scatchard coordinate sys-
tem are shown.
The TRAIL-R4 Gene Is Part of a TRAIL-R Cluster
interaction between TRAIL and TRAIL-R4 was confirmedLocated on Human Chromosome 8p
by autoradiographic analysis using soluble leucine zip-Analysis of two independent radiation hybrid panels us-
per (LZ)±TRAIL and TRAIL-R4 transiently expressed oning a primer pair specific for human TRAIL-R4 has
the cell surface of CVI/EBNA cells, as described pre-mapped the gene to human chromosome 8p22-21. By
viously (Degli-Esposti et al., 1997) (data not shown).linkage analysis the TRAIL-R4 gene has been placed
Quantitative equilibrium binding isotherms betweeninto a cluster, located approximately 49 cM from the
the TRAIL ligand and TRAIL-R4, determined using atelomere, that also contains the genes for TRAIL-R1,
TRAIL-R4-Fc chimera, demonstrated specific and satu-TRAIL-R2, and TRAIL-R3 (Degli-Esposti et al., 1997). Two
rable binding (Figure 3) via two classes of sites (Kd(high) 5similar TNFR family gene clusters, on chromosomes 1p
0.085 nM; Kd(low) 5 39.2 nM). Thus, this receptor bindsand 12p, have been described previously. However, in
the TRAIL ligand with affinities comparable to thosethis instance, all of the genes in the cluster are receptors
of the three previously characterized TRAIL receptorsfor a common ligand and share a much higher degree
(Degli-Esposti et al., 1997).of identity than other members of the TNFR family.
TRAIL-Induced Apoptosis Is InhibitedTRAIL-R4 Shows Widespread Tissue Distribution
by Soluble TRAIL-R4-FcThe mRNA expression of TRAIL-R4 in human tissues
To determine whether the extracellular ligand-bindingand tumor cell lines was determined by Northern blot
domain of TRAIL-R4 can successfully block TRAIL-analysis. A TRAIL-R4 transcript of approximately 4.0 kb
mediated activities, we tested the ability of a solublewas clearly detected in all tissues (Figure 2). Hybridiza-
TRAIL-R4-Fc fusion protein to block TRAIL-mediatedtion was also observed at positions 18S and 28S of
apoptosis of Jurkat T cells. Jurkat cells are highly sensi-ribosomal RNA migration, which we presume is not spe-
tive to TRAIL, and when cultured in its presence theycific for TRAIL-R4. The lowest detectable levels of hy-
are effectively killed within 6±12 hr. As expected, TRAIL-bridization to the 4.0 kb TRAIL-R4 transcript were ob-
induced apoptosis was efficiently and specifically inhib-served in thymus and spleen (Figure 2). This is similar
ited by coculturing with concentrated supernatants fromto the widespread tissue distribution observed for
CVI/EBNA cells transiently expressing soluble TRAIL-TRAIL-R1 (Pan et al., 1997b) and TRAIL-R2 (Pan et al.,
R4-Fc (Figure 4). Furthermore, TRAIL-R4-Fc was unable1997a; Sheridan et al., 1997; Walczak et al., 1997) but
to block Fas-L±mediated killing (data not shown), andcontrasts with the more restricted distribution observed
Fas-Fc was unable to block TRAIL-mediated killing (Fig-for TRAIL-R3 (Degli-Esposti et al., 1997; Pan et al.,
ure 4).1997a; Sheridan et al., 1997). In addition, TRAIL-R4 mes-
sage was expressed at a high level in three tumor cell
lines (A549, SW480, and HeLa S3) (Figure 2). TRAIL-R4 Does Not Signal Apoptosis
Two previously characterized members of the TRAIL-R
family have been shown to transmit a death signal (PanTRAIL-R4 Binds TRAIL
Given the identity that exists between the extracellular et al., 1997a, 1997b; Sheridan et al., 1997; Walczak et al.,
1997). Like other members of theTNFR family capable ofligand-binding domain of TRAIL-R4 and those of the
previously characterized TRAIL receptors, we predicted transducing such a response, TRAIL-R1 and TRAIL-R2
share an approximately 80 aa region of homology inTRAIL to be the ligand for thisnew receptor.The physical
Immunity
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Figure 4. TRAIL-R4-Fc Inhibits TRAIL-Mediated Killing
Soluble TRAIL-R4-Fc, TRAIL-R3-Fc, TRAIL-R2-Fc, TRAIL-R1-Fc, or
Fas-Fc or CD30-Fc proteins were added to cultures of Jurkat cells
in the presence of soluble LZ-TRAIL (150 ng/ml). The MTT readings
obtained in the absence and presence of LZ-TRAIL correspond to
the maximum and minimum viability values, respectively. All TRAIL-
R-Fc proteins blocked TRAIL-mediated apoptosis of Jurkat cells.
the cytoplasmic region that corresponds to the death
domain, the region critical for the induction of apoptotic
signals (Itoh and Nagata, 1993; Tartaglia et al., 1993). In Figure 5. TRAIL-R4 Impedes TRAIL-Mediated Killing of CVI/EBNA
contrast, TRAIL-R4 lacks 52 of the 76 amino acids that Cells
encode the predicted TRAIL-R1 and TRAIL-R2 death CVI/EBNA cells were transiently cotransfected with an expression
plasmid encoding the Escherichia coli lacZ gene plus an expressiondomain (Walczak et al., 1997), suggesting that this re-
plasmid for TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4, 41BB, or anceptor may not be capable of transducing an apoptotic
unrelated type 1 transmembrane protein (control). Forty-eight hourssignal.
after transfection the cells were incubated with or without soluble
Self-oligomerization of cytoplasmic signaling se- LZ-TRAIL (0.5 or 1.0 mg/ml) and assayed 16 hr later for apoptosis.
quences, as induced by overexpression, mimics ligand- Cells were checked for the morphological changes characteristic
mediated juxtaposition of the cytoplasmic regions re- of apoptosis and stained for b-galactosidase activity. The percent-
age of live cells was quantitated by scoring the percentage of stain-quired for productive signaling. Using such a system,
ing cells. The values plotted represent the mean and standard devia-both TRAIL-R1 and TRAIL-R2 were shown capable of
tion of three separate experiments.signaling apoptosis (Pan et al., 1997a, 1997b; Sheridan
et al., 1997; Walczak et al., 1997) (Figure 5). In contrast,
transient overexpression of TRAIL-R4 in CVI/EBNA cells TRAIL-R4 Induces NF-kB Activation
Despite its lack of a complete death domain, TRAIL-R4did not lead to cell death (Figure 5).
encodes what appears to be a functional cytoplasmic
signaling region. In several other members of the TNFRTRAIL-R4 Overexpression Confers Resistance
to TRAIL-Mediated Apoptosis family the cytoplasmic region also contains sequences
involved in activation of the transcription factor NF-kB.Given the inability of TRAIL-R4 to trigger an apoptotic
signal due to lack of the complete death domain se- Since resistance to apoptosis may involve activation of
NF-kB, leading to the induction of protective genes (Begquence, we investigated the possibility that this receptor
may actively modulate TRAIL signaling. To do so we and Baltimore, 1996; Van Antwerp et al., 1996), we tested
whether TRAIL-R4 is able to activate NF-kB directly.tested the effect of overexpression of TRAIL-R4 in cells
that are normally sensitive to TRAIL-mediated apoptosis. By using an electrophoretic mobility shift assay, we
found that in transfected 293/EBNA cells, overexpres-CVI-EBNA cells can be killed by incubation with soluble
LZ-TRAIL (Figure 5). These cells were transiently trans- sion of TRAIL-R4 showed activation of NF-kB relative
to cells transfected with vector alone (Figure 6). Trans-fected with plasmids encoding the full-length sequence
of TRAIL-R4, TRAIL-R3, 41BB, and a control type 1 fection of 293/EBNA cells with TRAIL alone also caused
significant NF-kB activation (Figure 6). The level of NF-transmembrane protein, and their sensitivity to soluble
LZ-TRAIL was assessed48 hr after transfection. Overex- kB activation induced by TRAIL and/or its receptors,
however, is inferior to that induced by TNFR1 (data notpression of TRAIL-R4 conferred complete resistance to
TRAIL-mediated killing (Figure 5). In contrast, TRAIL- shown) but similar to that induced by CD30 (Figure 6).
R3, 41BB, and the control protein were unable to dimin-
ish the sensitivity of CVI/EBNA cells to TRAIL. A minor Discussion
effect of TRAIL-R3 (,30% inhibition) was observed 6 hr
after the addition of LZ-TRAIL (data not shown); how- In this report we describe the cloning and characteriza-
tion of TRAIL-R4, a novel member of the TRAIL-R familyever, this inhibition was no longer observed at 16 hr.
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Figure 6. TRAIL-R4 Activates NF-kB
293/EBNA cells were transiently transfected with expression plas-
mids encoding soluble TRAIL (2.5 mg), TRAIL-R4 (1.0 mg 5 low; 5.0 Figure 7. The TRAIL Receptor Family
mg 5 high), CD30 (5.0 mg), or empty pDC409 vector (1.0 mg 5 low; A schematic representation of the four members of the TRAIL recep-
5.0 mg 5 high). Nuclear extracts were incubated with a 32P-labeled tor family. Open boxes, homologous domains; horizontal lines, the
NF-kB-specific probe. NF-kB activation was assessed by gel shift conserved cysteine residues. The amino acid length of the extracel-
analysis. Incubations with an oligonucleotide carrying a consensus lular linker and cytoplasmic regions are shown. Black boxes in the
NF-kB sequence (wt oligo) and an oligonucleotide carrying the same cytoplasmic regions represent death domains.The GPI anchor hold-
sequence but including a single point mutation (mut oligo), were ing TRAIL-R3 onto the cell surface is shown. TNFR1 and CAR1, the
included to determine the specificity of any band shifts. closest relatives of TRAIL-Rs, are shown for comparison.
encode the predicted TRAIL-R1 and TRAIL-R2 deathencoding a cell surface molecule capable of specific,
high-affinity interaction with the cytotoxic TRAIL ligand. domain (Walczak et al., 1997) plus an additional 22 resi-
dues to the end of the coding sequence. The portion ofTRAIL-R4 shows a typical type 1 membrane protein ar-
chitecture, with an extracellular ligand-binding region the death domain that is missing in TRAIL-R4 corre-
sponds to the region shown be essential for TNFR1 self-composed of three cysteine-rich pseudorepeats, the
first of which is truncated. association±induced apoptosis (Boldin et al., 1995), but
it may not be required for other signaling, includingTRAIL-R4 is the newest member of the TRAIL-R fam-
ily, which also includes three previously described NF-kB activation. We therefore predicted that, unlike
TRAIL-R3, the TRAIL-R4 receptor may be capable ofmembers (Figure 7). Two of the previously characterized
receptors, TRAIL-R1/DR4 (Pan et al., 1997b) and TRAIL- inducing direct signals other than apoptosis. Indeed, we
have shown that TRAIL-R4, like other members of theR2/DR5 (Pan et al., 1997a; Sheridan et al., 1997; Walczak
et al., 1997) induce apoptosis, whereas the third, TRAIL- TNFR family, including TRAIL-R1 and TRAIL-R2, is capa-
ble of directly signaling NF-kB activation, confirmingR3/TRID/DcR1 (Degli-Esposti et al., 1997; Pan et al.,
1997a; Sheridan et al., 1997), lacks a cytoplasmic do- that in this system apoptosis and NF-kB activation rep-
resent two independent signaling pathways.main and, as expected, does not signal apoptosis. Of
particular significance is that TRAIL-R4 carries a cyto- Since TRAIL-R4 is an actively signaling receptor we
investigated the possibility that it may dynamically mod-plasmic region lacking most of the death domain that
characterizes TRAIL-R1 and TRAIL-R2 (Figures 1A and ulate the cytotoxic activity of TRAIL. Overexpression of
TRAIL-R4 in cells normally killed by TRAIL conferred1C) and that has been shown to be essential for the
induction of apoptosis. To test whether TRAIL-R4 is complete resistance to the cytotoxic effect of this cyto-
kine, suggesting that expression of TRAIL-R4 may deter-indeed unable to signal apoptosis, we tested its ability
to induce cell death in a transient overexpression sys- mine the sensitivity of different cells and tissues to
TRAIL-mediated killing.tem. This system relies on the fact that the self-aggrega-
tion of death domain motifs induced by overexpression Other investigators have proposed that protection
against TRAIL-mediated cytotoxicity is conferred by thesimulates the ligand-mediated juxtaposition of signaling
sequences essential for productive signaling (Boldin presence of TRAIL-R3/TRID/DcR1 (Pan et al., 1997a;
Sheridan et al., 1997), and indeed the presence or ab-et al., 1995). Using this system, we have shown that
TRAIL-R4 cannot induce apoptosis. sence of TRID/DcR1 message has been taken as evi-
dence to explain the differential sensitivity of normalThe third member of the TRAIL-R family, TRAIL-R3/
TRID/DcR1, is unable to transduce an apoptotic signal tissues and tumor cell lines to the cytotoxic effects of
TRAIL (Pan et al., 1997a; Sheridan et al., 1997). In lightbecause it completely lacks a cytoplasmic domain. Un-
like this receptor, TRAIL-R4 contains a large cyto- of the present findings, however, this appears to be an
oversimplification of an increasingly complex biologicalplasmic domain that includes a portion of the canonical
death domain described by Tartaglia and Itoh (Itoh and system. First, the level of expression of TRAIL-R3/TRID/
DcR1 in normal tissues is variable, and significant levelsNagata, 1993; Tartaglia et al., 1993). The TRAIL-R4 par-
tial death domain includes 24 of the 76 amino acids that are detected only in peripheral blood lymphocytes,
Immunity
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Table 1. Correlation between TRAIL-R Expression and Sensitivity to TRAIL-Mediated Apoptosis
Cell Line Lineage Sensitivity to TRAIL-Mediated Apoptosis TRAIL-R1 TRAIL-R2 TRAIL-R3 TRAIL-R4
CVI/EBNA Fibroblast 11 1 2 2 2
293/EBNA Epithelial 2 6 1 1 1
PS1 B cell 111 1 1 2 1
RAJI B cell 11 1 1 2 2
Jurkat T cell 111 6 1 2 1
U937 Monocytic 11 1 1 1 NT
HL60 Monocytic 1 1 1 1 1
Sensitivity to TRAIL-mediated apoptosis was quantitated in appropriate killing assays using soluble LZ-TRAIL. TRAIL-R expression was
determined by PCR using locus-specific primer pairs. Northern analysis was also used for some of the illustrated lines, and in all cases it
corroborated the PCR-derived results.
NT, not tested.
spleen (Degli-Esposti et al., 1997), and lung (Sheridan cytotoxic effects of TRAIL by titration of adaptor pro-
teins or by recruitment of such proteins to a hetero-et al., 1997). Furthermore, extreme caution should be
taken when cell surface expression of the TRAIL-R3 complex that may result in the formation of an incom-
plete death-inducing signaling complex. In this regard,protein is predicted from message levels, especially be-
cause such extrapolations completely ignore the likely it will be relevant to determine whether signals gener-
ated via TRAIL-R4 are capable of blocking the apoptoticinfluence of secondary signaling mechanisms.
Second, the described decoy activity of TRAIL-R3 signals generated by other ligands in this family, such
as TNF and Fas ligand.appears to be limited. As shown by others, expression
of TRAIL-R3 reduces the killing potential of TRAIL. This As mentioned above, itmay be difficult to correlate the
expression of message for the different TRAIL receptorseffect, however, seems to be transient and at best par-
tial. As described in the Results section, we observed with sensitivity to TRAIL-mediated cytotoxicity, and
such a correlation may represent a nonphysiologicalan incomplete (z30%) inhibitory effect of TRAIL-R3 6
hr after addition of TRAIL. However, the inhibition was oversimplification of the system. We have analyzed the
sensitivity of several tumor cell lines in the context ofno longer observed at 16 hr. The extent of protection
conferred by TRAIL-R3 noted in this study is equivalent the expression of different TRAIL receptors. As shown
in Table 1, there is no clear correlation between theto that previously reported by others (Pan et al., 1997a;
Sheridan et al., 1997) and, together with the transient expression of the potential decoy receptors TRAIL-R3
and/or TRAIL-R4 and sensitivity to TRAIL. These datanature of the TRAIL-R3 protection, does not appear to
justify a major role for TRAIL-R3 as a universal decoy provide furtherevidence of the complexity of this system
and warn us that a great deal of further analysis is re-receptor for TRAIL. Further complexity is generated by
the discovery that TRAIL-R4 can bind TRAIL without quired to elucidate the biological role of TRAIL and its
receptors, and their potential as antitumor agents.eliciting an apoptotic signal and indeed, in the cell sys-
In conclusion, the identification of TRAIL-R4 adds fur-tem described in this report, it can completely block the
ther complexity to the biological relevance of the emerg-cytotoxic activities of TRAIL.
ing TRAIL receptor family. The physiological function ofThird, TRAIL-R4 retains the ability to signal NF-kB
each of these receptors remains to be elucidated. Thisactivation. Since NF-kB activation has been shown to
task may prove to be more difficult than expected sinceincrease the anti-apoptotic threshold of cells and tis-
the standard approach of targeted gene disruption maysues exposed to cytotoxic cytokines such as TNFa (Beg
not be completely straightforward: the genes encodingand Baltimore, 1996; Van Antwerp et al., 1996), it is
each of the described TRAIL receptors are located in apossible that TRAIL-R4 may similarly inhibit TRAIL-
chromosomal cluster and show a high degree of nucleo-induced apoptosis via the active induction of genes
tide identity. Continued evaluation of this system, how-whose products provide resistance to apoptosis. In this
ever, is imperative since it may provide the first cluescontext, it is worthy to note that (1) the sensitivity of
toward an understanding of the mechanisms that regu-several cells to the cytotoxic effects of TRAIL is en-
late the balance between cell survival and cell death.hanced in the absence of protein synthesis (Sheridan et
al., 1997; Griffiths and Kubin, personal communication),
and (2) expression of the Flice inhibitory protein (FLIP)
Experimental Procedureswas shown to effectively modulate TRAIL-induced
apoptosis (Irmler et al., 1997). Isolation of TRAIL-R4 cDNA
Fourth, the partial death domain in the cytoplasmic A cDNA sequence with homology to TRAIL-R1 (Pan et al., 1997b),
portion of TRAIL-R4 does not allow self-aggregation± TRAIL-R2 (Pan et al., 1997a; Sheridan et al., 1997; Walczak et al.,
1997), and TRAIL-R3 (Degli-Esposti et al., 1997; Pan et al., 1997a;induced apoptosis, but it retains a number of amino
Sheridan et al., 1997) was identified by screening peripheral bloodacids shown to play an essential role in TNFR1- and Fas-
lymphocyte and human foreskin fibroblast cDNA libraries. Amediated apoptosis (Itoh and Nagata, 1993; Tartaglia et
[32P]dCTP random-prime-labeled polymerase chain reaction (PCR)
al., 1993). This effect may occur through the recruitment product encompassing the cysteine-rich extracellular domain of
of secondary signaling factors. Thus, the incomplete TRAIL-R3 was used as the probe for screening. The sequence of
TRAIL-R4 was obtained using the ABI PRISM Dye Terminator Cycledeath domain of TRAIL-R4 may actively prevent the
TRAIL-R4, a Fourth Signaling Receptor for TRAIL
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Sequencing Ready Reaction Kit, Protocol PN402078 (Perkin Elmer, correlates with a decrease in the number of cells expressing b-galac-
tosidase (Hsu et al., 1995). Each experiment was repeated threeFoster City, CA).
times.
Chromosomal Mapping
Two independent radiation hybrid panels, the Stanford G3 Radiation Electrophoretic Mobility Shift Assay
Hybrid Panel RH01 and the Genebridge 4 Radiation Hybrid Panel Nuclear extracts were prepared from 293/EBNA cells transfected
RH02.02 (Research Genetics, Huntsville, AL)were used to determine with TRAIL, TRAIL-R4, CD30, or control vector 48 hr after transfec-
the chromosomal location of TRAIL-R4. Each panel was screened tion, as described (Yao et al., 1995). Oligonucleotides containing an
with a set of oligonucleotide primers (59-CACTACCTTATCATCATAG NF-kB binding site were annealed, radiolabeled with [32P]dATP, and
TGGTTTT-39 and 59-GAAGGACATGAACGCCGCCGGAAAAG-39) combined with 10 mg of nuclear extracts for 20 min at room tempera-
that specifically amplify human TRAIL-R4 from genomic DNA. The ture. The specificity of the reaction was confirmed by competition
results were electronically submitted to the appropriate servers with 50-fold molar excess of nonlabeled wild-type oligonucleotides
(www.shgc.stanford.edu and www.genome.wi.mit.edu) for linkage or oligonucleotides containing a mutated NF-kB binding site. The
analysis. protein±DNA complexes were resolved by 6% polyacrylamide gel
electrophoresis in 0.25 3 Tris-borate-EDTA buffer and visualized
Northern Analysis by autoradiography.
A human multiple tissue Northern blot and a tumor cell line Northern
blot (Clontech, Palo Alto, CA) were probed with a 32P-labeled ribo- Acknowledgments
probe encompassing 248 nucleotides of the 39 untranslated region
of TRAIL-R4 immediately following the termination codon. The blots The authors are grateful to C-P. Huang for sequencing, C. Rauch
were hybridized overnight at 638C in Stark's buffer (Wahl et al., 1979) for purification of LZ-TRAIL, K. Maggiora for transfections, and M.
and washed twice for 20 min in 0.13 SSC, 0.1% SDS at 688C. Petersen for purification of soluble Fc proteins.
Hybridizing bands were visualized by autoradiography.
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